The Sarcoma DOT has a broad spectrum of investigations to better understand how these groups of deadly but rare cancers develop and how to identify the best strategies to treat these cancers. We are particularly interested in the molecular pathways by which these cancers can kill. We are also looking at the inherited and familial risk for disease and are concerned about how these cancers impact sarcoma survivors later in life.
As sarcomas affect both children and adults we have a strong collaborative spirit with Primary Children’s Hospital and the Department of Pediatrics at the University of Utah.
|For More Information|
Overview of Projects:
The Sarcoma DOT is dedicated to unlocking the mysteries of these cancers and finding better ways to cure patients and enhance their lives. Our investigators bring an expansive and veritable depth of expertise in sarcoma investigation. Collaborating with other authorities from around the world, our investigators strive to understand why people develop these types of cancers. To conduct this research, we receive precious tumor samples and DNA from patients living in numerous countries from around the globe. In addition to investigating who might be at risk, we are dedicated to finding molecular targets to improve survival. In particular, we have leading edge investigations in Ewings and Synovial Sarcomas, among others, collaborating with internationally renowned scientists and Nobel Laureates to understand why these cancers tend to spread and ways by which this process can be stopped. With some of the most advanced imaging techniques in the world our scientists are able to understand, with molecular accuracy, how these novel treatments might work to cure patients.
When someone is stricken with sarcoma, not only is their life threatened, but they also face deficits in their quality of life. Many of our patients are children, adolescents and young adults whose entire lives lie before them. We are dedicated to making sure those lives are healthy and happy. Many of the current treatments for sarcoma have short, and potentially long-term, side effects. While striving to minimize these health effects, our investigators are researching strategies to address patients’ health care needs and concerns as they reintegrate into their normal lives.
From clinician-scientists to epidemiologists to cancer geneticists to laboratory scientists and population-population based investigators, we are dedicated to the sarcoma patients of today and tomorrow.
While Sarcoma Services has a rich and long tradition in Utah, the new DOT at HCI is a vital step to optimize how we can better serve our patients through innovative research. Federal and foundation research funds for these rare and deadly tumors are quite limited. As such, sarcoma is considered an “orphan” disease and we are highly dependent upon philanthropic gifts and donations to support our programmatic efforts. Our DOT meets monthly and has an ambitious agenda to make sure that any and all of our donors’ generosities are used to better understand, treat and care for our patients today and tomorrow. Working together, the Sarcoma DOT will improve the lives of all patients with sarcoma both locally and around the globe.